Cargando…
Confusion between Two Amphotericin B Formulations Leading to a Paediatric Rehospitalisation
A heavily immunosuppressed, 43-kg, 9-year-old patient was recovering from a bone marrow transplant. Primary prophylaxis against invasive fungal infections was liposomal amphotericin B (AmBisome(®), 2.3 mg/kg [100 mg] two times per week). Once home, following a first amphotericin B infusion, he prese...
Autores principales: | Fleury, Mapi, Fonzo-Christe, Caroline, Normand, Charline, Bonnabry, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005581/ https://www.ncbi.nlm.nih.gov/pubmed/27747684 http://dx.doi.org/10.1007/s40800-016-0028-6 |
Ejemplares similares
-
Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015) -
Design of amphotericin B oral formulation for antifungal therapy
por: Liu, Min, et al.
Publicado: (2017) -
PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients
por: Desnoyer, Aude, et al.
Publicado: (2017) -
Botulinum neurotoxin formulations: overcoming the confusion
por: Samizadeh, Souphiyeh, et al.
Publicado: (2018) -
Nephrotoxicity of three formulations of amphotericin B: trial sequential analysis
por: Caputo, Rosaria, et al.
Publicado: (2020)